首页 › 慢性淋巴细胞白血病 › 俄亥俄州 › Columbus
Columbus OH 慢性淋巴细胞白血病临床试验
29项针对 慢性淋巴细胞白血病的研究正在 Columbus及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
招募中3 期
- OSU Comprehensive Cancer Center, Columbus
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
HPC Offered for PRESERVE Expansion
招募中观察性研究
- The Ohio State University Medical Center, Columbus
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
招募中1 期
- The James Cancer Hospital and Solove Research Institute, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- 以及另外 8 项
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- 以及另外 8 项
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- The Ohio State University, Columbus
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
招募中1/2 期
- Research Site, Columbus
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- The Ohio State University Wexner Medical Center, Columbus
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
招募中2 期
- The Ohio State University Comprehensive Cancer Center, Columbus
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
招募中3 期
- Study Site 104, Columbus
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
招募中1 期
- The Ohio State University, Columbus
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
招募中1 期
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- The Ohio State University, Columbus
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- The Ohio State University - The James Cancer Hospital, Columbus
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
招募中2 期
- The Ohio State University /ID# 230439, Columbus
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- The Ohio State University Comprehensive Cancer Center, Columbus
其他城市的 慢性淋巴细胞白血病试验
- Boston, MA31 项研究
- Durham, NC28 项研究
- Washington, DC22 项研究
- Seattle, WA22 项研究
- Rochester, MN20 项研究
- New York City, NY20 项研究
- Houston, TX18 项研究
- Baldwin Park, CA18 项研究
- Cincinnati, OH15 项研究
- Milwaukee, WI15 项研究
- Chicago, IL14 项研究
- Nashville, TN13 项研究
Columbus的其他研究
- 非小细胞肺癌57 项研究
- 癌症（所有类型）40 项研究
- 乳腺癌39 项研究
- 卵巢癌39 项研究
- 肺癌36 项研究
- 急性髓系白血病34 项研究
- 转移性癌症25 项研究
- 多发性骨髓瘤25 项研究
- 前列腺癌25 项研究
- 子宫内膜癌24 项研究
- 结直肠癌24 项研究
- 黑色素瘤21 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。